Madrigal Pharmaceuticals, Inc. Forecast, price target & analysts
Madrigal Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Madrigal Pharmaceuticals, Inc. Classifications & Recommendation:
Madrigal Pharmaceuticals, Inc. Price Target
| Target Price | $568.14 |
| Price | $602.82 |
| Deviation |
5.75%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Madrigal Pharmaceuticals, Inc. 2026 .
The average Madrigal Pharmaceuticals, Inc. target price is $568.14.
This is
5.75%
register free of charge
$682.50
13.22%
register free of charge
$460.56
23.60%
register free of charge
|
|
| A rating was issued by 23 analysts: 21 Analysts recommend Madrigal Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Madrigal Pharmaceuticals, Inc. stock has an average upside potential 2026 of
5.75%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 180.13 | 965.59 |
| 436.05% | ||
| EBITDA Margin | -275.79% | -30.43% |
| 88.97% | ||
| Net Margin | -258.64% | -23.87% |
| 90.77% |
18 Analysts have issued a sales forecast Madrigal Pharmaceuticals, Inc. 2025 . The average Madrigal Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Madrigal Pharmaceuticals, Inc. EBITDA forecast 2025. The average Madrigal Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Madrigal Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Madrigal Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -21.90 | -10.15 |
| 9.55% | 53.65% | |
| P/E | negative | |
| EV/Sales | 13.37 |
19 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast for earnings per share. The average Madrigal Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Madrigal Pharmaceuticals, Inc....
Current Madrigal Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Dec 19 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Dec 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 19 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Dec 19 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Dec 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 20 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 19 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
